协同TLR配体的纳米制剂增强抗溶组织内阿米巴疫苗接种效果
本研究在CBA/J小鼠中评估纳米脂质体佐剂系统对溶组织内阿米巴Gal/GalNAc凝集素LecA抗原的黏膜免疫增强作用。含TLR4和TLR7/8激动剂的脂质体配方可诱导肠道IgA、血浆IgG2a/IgG1、IFN-γ和IL-17A;黏膜初免加非肠道加强产生高黏膜IgA反应,抑制寄生虫黏附哺乳动物细胞,加入全反式维甲酸进一步改善黏膜IgA反应,免疫保护效率最高达55%。
要点
- 含TLR4和TLR7/8激动剂的脂质体配方被选中,因其能产生肠道IgA、血浆IgG2a/IgG1、IFN-γ和IL-17A。
- 黏膜初免后非肠道加强产生高黏膜IgA反应,抑制寄生虫黏附哺乳动物细胞。
- 方案中加入全反式维甲酸进一步改善黏膜IgA反应,免疫保护效率最高达55%。
核心结论
- 含TLR激动剂的纳米脂质体递送系统是开发抗肠道病原体疫苗的有前景方向,尤其在需要多方面免疫反应时。
研究设计与样本
- CBA/J小鼠免疫实验,比较含合成TLR激动剂的明矾、乳剂或脂质体配方。
主要发现
- 含TLR4和TLR7/8激动剂的脂质体配方被选中,基于其产生肠道IgA、血浆IgG2a/IgG1、IFN-γ和IL-17A的能力。
- 黏膜初免后非肠道加强产生高黏膜IgA反应,抑制寄生虫黏附哺乳动物细胞。
- 方案中加入全反式维甲酸进一步改善黏膜IgA反应。
- 免疫保护效率最高达55%。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Diarrheal infectious diseases represent a major cause of global morbidity and mortality. There is an urgent need for vaccines against diarrheal pathogens, especially parasites. Modern subunit vaccines rely on combining a highly purified antigen with an adjuvant to increase their efficacy. In the present study, we evaluated the ability of a nanoliposome adjuvant system to trigger a strong mucosal immune response to the Entamoeba histolytica Gal/GalNAc lectin LecA antigen. CBA/J mice were immunized with alum, emulsion or liposome based formulations containing synthetic TLR agonists. A liposome formulation containing TLR4 and TLR7/8 agonists was selected based on its ability to generate intestinal IgA, plasma IgG2a/IgG1, IFN-γ and IL-17A. Immunization with a mucosal prime followed by a parenteral boost generated a high mucosal IgA response that inhibited adherence of parasites to mammalian cells. Inclusion of the immune potentiator all-trans retinoic acid in the regimen further improved the mucosal IgA response. Immunization protected from infection with up to 55% efficacy. Our results show that a nanoliposome delivery system containing TLR agonists is a promising prospect for the development of vaccines against enteric pathogens, especially when a multifaceted immune response is desired.
引用
- Abhyankar MM, Noor Z, Tomai MA, et al. Nanoformulation of synergistic TLR ligands to enhance vaccination against Entamoeba histolytica. Vaccine. 2017. PMID: 28089548. doi:10.1016/j.vaccine.2016.12.057
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。